Momordin Ic targets SREBP1 to disrupt lipid homeostasis and trigger synergistic apoptosis-ferroptosis in triple-negative breast cancer.
2/5 보강
OpenAlex 토픽 ·
Ferroptosis and cancer prognosis
Cancer, Lipids, and Metabolism
Ferrocene Chemistry and Applications
[BACKGROUND] Triple-negative breast cancer (TNBC) constitutes a clinically challenging disease subtype characterized by high metastatic potential and unsatisfactory treatment outcomes.
APA
Yao Cheng, Yu-zhe Shi, et al. (2026). Momordin Ic targets SREBP1 to disrupt lipid homeostasis and trigger synergistic apoptosis-ferroptosis in triple-negative breast cancer.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 155, 158190. https://doi.org/10.1016/j.phymed.2026.158190
MLA
Yao Cheng, et al.. "Momordin Ic targets SREBP1 to disrupt lipid homeostasis and trigger synergistic apoptosis-ferroptosis in triple-negative breast cancer.." Phytomedicine : international journal of phytotherapy and phytopharmacology, vol. 155, 2026, pp. 158190.
PMID
42008854 ↗
Abstract 한글 요약
[BACKGROUND] Triple-negative breast cancer (TNBC) constitutes a clinically challenging disease subtype characterized by high metastatic potential and unsatisfactory treatment outcomes. Developing innovative pharmacological interventions is therefore critically important. The plant-derived compound Momordin Ic (MMD) has demonstrated preliminary anti-neoplastic activity; however, its therapeutic potential against TNBC and corresponding mechanisms require systematic investigation.
[PURPOSE] This study aims to systematically investigate the therapeutic potential and underlying mechanisms of MMD against triple-negative breast cancer.
[METHODS] MTT, EdU, colony formation, wound healing, transwell, flow cytometry, and xenograft mouse models. Mechanisms were explored using transcriptomic sequencing, molecular docking, cellular thermal shift assay (CETSA), and western blotting.
[RESULTS] MMD substantially suppressed the growth, movement, and infiltration of TNBC cells, led to G2/M phase blockade and induced mitochondrial apoptosis together with ferroptosis. Mechanistically, MMD was found to directly bind to the transcription factor sterol regulatory element-binding protein 1 (SREBP1), suppressing its activity and downstream lipogenic genes (e.g. ACC1, SCD1). This led to disrupted lipid homeostasis, evidenced by reduced neutral lipid droplets and total cholesterol. Overexpression of SREBP1 partially reversed the anti-tumor effects of MMD. Furthermore, MMD robustly suppressed tumor growth in a xenograft model without observable toxicity.
[CONCLUSIONS] Our findings indicate that MMD produces anti-TNBC responses through engagement of SREBP1 as a key functional mediator, causing metabolic disturbance and coordinated activation of apoptotic and ferroptotic pathways. These findings suggest that MMD could be further explored as a treatment candidate and highlight the SREBP1 pathway as a valuable target for TNBC treatment.
[PURPOSE] This study aims to systematically investigate the therapeutic potential and underlying mechanisms of MMD against triple-negative breast cancer.
[METHODS] MTT, EdU, colony formation, wound healing, transwell, flow cytometry, and xenograft mouse models. Mechanisms were explored using transcriptomic sequencing, molecular docking, cellular thermal shift assay (CETSA), and western blotting.
[RESULTS] MMD substantially suppressed the growth, movement, and infiltration of TNBC cells, led to G2/M phase blockade and induced mitochondrial apoptosis together with ferroptosis. Mechanistically, MMD was found to directly bind to the transcription factor sterol regulatory element-binding protein 1 (SREBP1), suppressing its activity and downstream lipogenic genes (e.g. ACC1, SCD1). This led to disrupted lipid homeostasis, evidenced by reduced neutral lipid droplets and total cholesterol. Overexpression of SREBP1 partially reversed the anti-tumor effects of MMD. Furthermore, MMD robustly suppressed tumor growth in a xenograft model without observable toxicity.
[CONCLUSIONS] Our findings indicate that MMD produces anti-TNBC responses through engagement of SREBP1 as a key functional mediator, causing metabolic disturbance and coordinated activation of apoptotic and ferroptotic pathways. These findings suggest that MMD could be further explored as a treatment candidate and highlight the SREBP1 pathway as a valuable target for TNBC treatment.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Biological Logic-Gated DNA Self-Assembly Strategy for Precision Tumor Imaging and Selective Activation of the cGAS-STING Pathway.
- Recent Advances and Emerging Directions in Machine Learning-Based Breast Cancer Drug Discovery: A Comprehensive Review.
- Molecule-Level Interpretable SERS Diagnosis of Prostate Cancer via Prostatic Fluid Metabolites and Extracellular Vesicles.
- Prognostic value of baseline F-FDG PET/CT metabolic parameters combined with clinical and pathological features in surgically resected ALK-positive non-small cell lung cancer.
- In situ generation of hydroperoxide-rich-peptide-based nano-assemblies for self-amplified magnetic resonance imaging-guided synergistic tumor chemo/chemodynamic/ferroptotic therapy.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- A herbal formulation inhibits growth and survival of lung cancer cells through DNA damage and apoptosis - in vitro and in vivo studies.
- Mitocurcumin induces ROS-/JNK-mediated paraptosis to overcome chemoresistance in non-small cell lung cancer.
- Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia.
- Editorial: Altered metabolic traits in gastro-intestinal tract cancers, volume II.
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.